Copper Chelator
Wilson Disease
Pre-clinicalActive
Key Facts
About DepYmed
DepYmed is a clinical-stage biotech leveraging a proprietary platform to develop selective inhibitors of protein tyrosine phosphatase 1B (PTP1B) and copper chelators. The company is advancing two orally bioavailable small molecules into clinical trials, with its lead asset, DPM-1003 for Rett Syndrome, having recently received FDA clearance to initiate a Phase 1 trial. With a focus on rare diseases and oncology, DepYmed is backed by venture capital and led by a team with deep expertise in drug development and phosphatase biology.
View full company profileOther Wilson Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Trientine Tetrahydrochloride (Cuprior®/Cuvrior®) | Orphalan | Approved |
| UX701 | Ultragenyx Pharmaceutical | Phase 1/2 |
| Undisclosed (Liver) | Prime Medicine | Preclinical |
| ALXN1840 | Monopar Therapeutics | Phase 3 |